Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Rezafungin in Suspected Intra-Abdominal Candidiasis
2025-521854-40-00Phase 4Authorised
- Sponsor
- Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
- Start
- Aug 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rezafungin in Intra-abdominal candidiasis (IAC) and candidal peritonitis, sponsored by Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal. Primary endpoints: Peritoneal diffusion rate of Rezafungin and Peritoneal fluid death curves. Planned start Aug 2025; status: authorised.
02
Drugs
rezafungin
03
Conditions
Intra-abdominal candidiasis (IAC)candidal peritonitis
Beyond the preview
Go deeper on 2025-521854-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521854-40-00.